Study details
Enrolling now
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT IDNCT03383575ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
63
Study length
about 9.1 years
Ages
12+
Locations
3 sites in MD, OH, TX
About this study
This trial is testing azacitidine and enasidenib as a treatment for patients with IDH2-mutant myelodysplastic syndrome. The goal is to assess the safety and effectiveness of these medications in stopping cancer cell growth.
Based on ClinicalTrials.gov records.
What participants do
- 1.Quality-of-Life Assessment
- 2.Take Azacitidine
- 3.Take Enasidenib
PhasePhase 2
DrugAzacitidine
Routeinjection
Primary goalIncidence of adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
azacitidine, enasidenib
Drug routes
injection, subcutaneous, oral (Oral Tablet)
Endpoints
Primary: Incidence of adverse events, Overall response rate
Secondary: Event-free survival (EFS), Overall survival (OS)
Body systems
Musculoskeletal, Oncology